Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.62 |
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.57 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.54 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.54 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789789 | 0.97 | HRH3 (0.65) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 | |
| SCHEMBL4432948 | 0.90 | L3MBTL3 (0.55) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL1791338 | 0.90 | HRH3 (0.61) | HRH3L3MBTL3L3MBTL1KDM2B | |
| SCHEMBL1790933 | 0.90 | HRH3 (0.56) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 | |
| SCHEMBL4528427 | 0.88 | HRH3 (0.56) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 | |
| SCHEMBL1791391 | 0.87 | HRH3 (0.57) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 | |
| SCHEMBL1790480 | 0.87 | HRH3 (0.54) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 | |
| SCHEMBL4529106 | 0.85 | HRH3 (0.53) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL5663691 | 0.85 | HRH3 (0.59) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 | |
| SCHEMBL1787136 | 0.84 | HRH3 (0.56) | HRH3L3MBTL3L3MBTL1KDM2BMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885L3MBTL3 1024/4885L3MBTL1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.